Total Funding
40
61
Total FundingGrant raised
Growth Score
-5 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
66027
Tachyon Therapeutics develops novel, selective compounds to improve the treatment of cancer.
- Frank Perabo: Chief Executive OfficerPast Role: ESSA Pharma, CMO
- Daniel Simon: Senior Consultant, Business Development
About the Company
Tachyon Therapeutics develops novel, selective compounds to improve the treatment of cancer. The company is currently conducting Phase 1 clinical research in patients with advanced cancer to assess the safety, pharmacokinetics, and anti-tumor effectiveness of TACH101. The programs will be advanced in a timely, innovative, high-quality, and
scientifically sound manner.
